BACKGROUND: Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer with poorly understood prognostic variables. The purpose of this study was to define the prognostic impact of HER-2 status on survival outcomes of patients with IBC. METHODS: In all, 179 patients with IBC, diagnosed between 1989 and 2005, with known HER-2 status, and treated with an anthracycline-based chemotherapy regimen without trastuzumab, were included in the analysis. Patients with HER-2-positive disease who received trastuzumab at the time of disease recurrence were included. Survival outcomes were estimated by the Kaplan-Meier product limit method and compared across groups using the log-rank statistic. A Cox proportional hazards model was fitted to determine the association of survival outcomes with HER-2 status after adjusting for patient and tumor characteristics. RESULTS: A total of 111 patients (62%) had HER-2-negative disease and 68 (38%) had HER-2-positive disease. The median follow-up among all patients was 35 months. At the time of the analysis, 62 patients (55.9%) with HER-2-negative disease and 42 patients (61.8%) with HER-2-positive disease had a recurrence. Thirty-one patients (73.8%) with HER-2-positive disease who had a disease recurrence went on to receive trastuzumab. On univariate analysis, no statistically significant difference was observed for either recurrence-free survival (P = .75) or overall survival (P = .24) between patients who had HER-2-positive disease and those who had HER-2-negative disease. In a multivariate model, HER-2 status did not appear to significantly affect recurrence-free survival (hazards ratio [HR] of 0.75; 95% confidence interval [95% CI], 0.46-1.22 [P = .241]). In the multivariate model, patients with HER-2-positive disease had a decreased hazard of death (HR of 0.56; 95% CI, 0.34-0.93 [P = .024]) compared with patients with HER-2-negative disease. CONCLUSIONS: HER-2 status, in the absence of trastuzumab, did not appear to significantly affect recurrence-free survival. After adjusting for other characteristics, the addition of trastuzumab in the metastatic setting significantly improved survival in the HER-2-positive group above and beyond that of the HER-2-negative group. This gives us further insight into the biology of this aggressive disease and underlines the major effect of targeted intervention.
BACKGROUND:Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer with poorly understood prognostic variables. The purpose of this study was to define the prognostic impact of HER-2 status on survival outcomes of patients with IBC. METHODS: In all, 179 patients with IBC, diagnosed between 1989 and 2005, with known HER-2 status, and treated with an anthracycline-based chemotherapy regimen without trastuzumab, were included in the analysis. Patients with HER-2-positive disease who received trastuzumab at the time of disease recurrence were included. Survival outcomes were estimated by the Kaplan-Meier product limit method and compared across groups using the log-rank statistic. A Cox proportional hazards model was fitted to determine the association of survival outcomes with HER-2 status after adjusting for patient and tumor characteristics. RESULTS: A total of 111 patients (62%) had HER-2-negative disease and 68 (38%) had HER-2-positive disease. The median follow-up among all patients was 35 months. At the time of the analysis, 62 patients (55.9%) with HER-2-negative disease and 42 patients (61.8%) with HER-2-positive disease had a recurrence. Thirty-one patients (73.8%) with HER-2-positive disease who had a disease recurrence went on to receive trastuzumab. On univariate analysis, no statistically significant difference was observed for either recurrence-free survival (P = .75) or overall survival (P = .24) between patients who had HER-2-positive disease and those who had HER-2-negative disease. In a multivariate model, HER-2 status did not appear to significantly affect recurrence-free survival (hazards ratio [HR] of 0.75; 95% confidence interval [95% CI], 0.46-1.22 [P = .241]). In the multivariate model, patients with HER-2-positive disease had a decreased hazard of death (HR of 0.56; 95% CI, 0.34-0.93 [P = .024]) compared with patients with HER-2-negative disease. CONCLUSIONS:HER-2 status, in the absence of trastuzumab, did not appear to significantly affect recurrence-free survival. After adjusting for other characteristics, the addition of trastuzumab in the metastatic setting significantly improved survival in the HER-2-positive group above and beyond that of the HER-2-negative group. This gives us further insight into the biology of this aggressive disease and underlines the major effect of targeted intervention.
Authors: N T Ueno; A U Buzdar; S E Singletary; F C Ames; M D McNeese; F A Holmes; R L Theriault; E A Strom; B J Wasaff; L Asmar; D Frye; G N Hortobagyi Journal: Cancer Chemother Pharmacol Date: 1997 Impact factor: 3.333
Authors: Minna Tanner; Jorma Isola; Tom Wiklund; Björn Erikstein; Pirkko Kellokumpu-Lehtinen; Per Malmström; Nils Wilking; Jonas Nilsson; Jonas Bergh Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544
Authors: Elizabeth Turpin; Ivan Bièche; Philippe Bertheau; Louis-François Plassa; Florence Lerebours; Anne de Roquancourt; Martine Olivi; Marc Espié; Michel Marty; Rosette Lidereau; Michel Vidaud; Hughes de Thé Journal: Oncogene Date: 2002-10-24 Impact factor: 9.867
Authors: Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2006-04-10 Impact factor: 44.544
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Erika Resetkova; Ana M Gonzalez-Angulo; Nour Sneige; Timothy J Mcdonnell; Aman U Buzdar; Shu Wan Kau; Yuko Yamamura; James M Reuben; Gabriel N Hortobagyi; Massimo Cristofanilli Journal: Cancer Date: 2004-09-01 Impact factor: 6.860
Authors: Aida Kuzucan; Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Philip M Carpenter; Peter T Fwu; Hon J Yu; David J B Hsiang; Karen T Lane; John A Butler; Stephen A Feig; Min-Ying Su Journal: Clin Breast Cancer Date: 2012-04 Impact factor: 3.225
Authors: Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; David Schottenfeld; Sofia D Merajver Journal: Breast Cancer Res Treat Date: 2012-06-26 Impact factor: 4.872
Authors: Ivette J Suárez-Arroyo; Yismeilin R Feliz-Mosquea; Juliana Pérez-Laspiur; Rezina Arju; Shah Giashuddin; Gerónimo Maldonado-Martínez; Luis A Cubano; Robert J Schneider; Michelle M Martínez-Montemayor Journal: Am J Cancer Res Date: 2016-08-01 Impact factor: 6.166
Authors: S Dawood; S D Merajver; P Viens; P B Vermeulen; S M Swain; T A Buchholz; L Y Dirix; P H Levine; A Lucci; S Krishnamurthy; F M Robertson; W A Woodward; W T Yang; N T Ueno; M Cristofanilli Journal: Ann Oncol Date: 2010-07-05 Impact factor: 32.976
Authors: Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; Mousumi Banerjee; Laura S Rozek; David Schottenfeld; Joe B Harford; Sofia D Merajver Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-10-25 Impact factor: 4.254
Authors: Taiwo Adesoye; Oluwatowo Babayemi; Lauren M Postlewait; Sarah M DeSnyder; Susie X Sun; Wendy A Woodward; Naoto T Ueno; Kelly K Hunt; Anthony Lucci; Mediget Teshome Journal: Ann Surg Oncol Date: 2021-07-22 Impact factor: 5.344
Authors: Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Philip M Carpenter; Christine E McLaren; Wen-Pin Chen; Peter T Fwu; David J B Hsiang; Karen T Lane; John A Butler; Min-Ying Su Journal: J Surg Oncol Date: 2013-10-28 Impact factor: 3.454
Authors: Jason A Zell; Walter Y Tsang; Thomas H Taylor; Rita S Mehta; Hoda Anton-Culver Journal: Breast Cancer Res Date: 2009-02-19 Impact factor: 6.466